Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M141,139Revenue $M12,927Net Margin (%)29.8Z-Score18.4
Enterprise Value $M138,948EPS $1.5Operating Margin %38.8F-Score6
P/E(ttm))37.0Cash Flow Per Share $0Pre-tax Margin (%)38.4Higher ROA y-yN
Price/Book24.510-y EBITDA Growth Rate %18.8Quick Ratio1.0Cash flow > EarningsY
Price/Sales10.85-y EBITDA Growth Rate %19.6Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %7.3ROA % (ttm)38.3Higher Current Ratio y-yN
Dividend Yield %1.6Insider Buy (3m)0ROE % (ttm)69.3Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M2,650ROI % (ttm)69.1Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 53.2614%Reduce -52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 53.2617%Reduce -33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 53.2620%Reduce -21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.886
($34.84)
$ 53.2635%Add 58.71%310,970
NVORuane Cunniff 2013-06-30 Buy 0.04%$30.11 - $35.33
($33.29)
$ 53.2637%New holding34,640
NVOJohn Hussman 2012-09-30 Sold Out -0.01%$28.83 - $32.15
($30.65)
$ 53.2642%Sold Out0
NVOKen Fisher 2012-06-30 Add1.01%$25.98 - $30.38
($28.44)
$ 53.2647%Add 519.97%2,786,828
NVOJohn Hussman 2011-09-30 Buy 0.01%$19.46 - $25.45
($22.27)
$ 53.2658%New holding5,000
NVOKen Fisher 2011-06-30 Add0.06%$23.4 - $26.29
($24.91)
$ 53.2653%Add 68.56%456,434
NVOJohn Keeley 2011-06-30 Sold Out -0.01%$23.4 - $26.29
($24.91)
$ 53.2653%Sold Out0
NVOKen Fisher 2011-03-31 Buy 0.09%$22.16 - $25.59
($23.8)
$ 53.2655%New holding270,785
NVOJohn Keeley 2010-12-31 Buy 0.01%$18.2 - $22.43
($20.77)
$ 53.2661%New holding2,780
NVOVanguard Health Care Fund 2010-09-30 Sold Out -0.19%$16.23 - $19.85
($17.64)
$ 53.2667%Sold Out0
NVOVanguard Health Care Fund 2010-06-30 Reduce-0.08%$14.8 - $17.06
($15.97)
$ 53.2670%Reduce -42.86%400,000
NVOTom Gayner 2010-03-31 Add0.31%$12.77 - $15.83
($14.23)
$ 53.2673%Add 39.04%231,500
NVOVanguard Health Care Fund 2010-03-31 Reduce-0.04%$12.77 - $15.83
($14.23)
$ 53.2673%Reduce -12.50%700,000
NVOTom Gayner 2009-12-31 Buy 0.75%$12.43 - $13.87
($13.03)
$ 53.2676%New holding166,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVO :

    Quarterly/Annual Reports about NVO:

      News about NVO:

      Articles On GuruFocus.com
      These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
      To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
      Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR Feb 09 2015 
      Examining The Three Largest Guru Portfolios Oct 24 2014 
      Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
      Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
      GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 


      More From Other Websites
      Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog Mar 26 2015
      Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog Mar 26 2015
      Red Hat, Signet Top Buy Points En Route To New Highs Mar 26 2015
      Business Highlights Mar 26 2015
      Novo Nordisk (NVO) Stock Gains Today on Drug Application Resubmission Mar 26 2015
      Novo Nordisk to Refile Tresiba in the U.S. on Interim Analysis Mar 26 2015
      The Investor's Solution to Low, Low Interest Rates: Part I Mar 26 2015
      Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog Mar 26 2015
      Novo Nordisk's Saxenda Gets EU Approval for Obesity - Analyst Blog Mar 24 2015
      Bristol-Myers in Autoimmune Program Deal Mar 24 2015
      Pfizer Announces Publication of CAPiTA Data on Prevenar 13 - Analyst Blog Mar 19 2015
      Novo Nordisk On Diversity In Diabetes Trials: "We Could Do Better" Mar 19 2015
      Valeant (VRX) Prices Shares to Finance Salix Acquisition - Analyst Blog Mar 18 2015
      AstraZeneca Presents Encouraging Heart Drug Brilinta Data - Analyst Blog Mar 18 2015
      Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog Mar 18 2015
      Novo Nordisk A/S - Share repurchase programme Mar 18 2015
      Weight-Loss Drugs Seek Acceptance From Patients and Physicians Mar 16 2015
      Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog Mar 09 2015
      Novo Nordisk A/S gennemfører succesfuld børsnotering af NNIT A/S Mar 06 2015
      Novo Nordisk's Oral Semaglutide Positive in Diabetes Study - Analyst Blog Feb 23 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      Gintaras58
      ReplyGintaras58 - 1 year ago
      few excellent prducts to come soon
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK